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Abstract
Although Inflammatory Breast Cancer (IBC) is recognized as the most metastatic variant of locally advanced breast
cancer, the molecular basis for the distinct clinical presentation and accelerated program of metastasis of IBC is
unknown. Reverse phase protein arrays revealed activation of the receptor tyrosine kinase, anaplastic lymphoma
kinase (ALK) and biochemically-linked downstream signaling molecules including JAK1/STAT3, AKT, mTor, PDK1, and
AMPKβ in pre-clinical models of IBC. To evaluate the clinical relevance of ALK in IBC, analysis of 25 IBC patient
tumors using the FDA approved diagnostic test for ALK genetic abnormalities was performed. These studies
revealed that 20/25 (80%) had either increased ALK copy number, low level ALK gene amplification, or ALK gene
expression, with a prevalence of ALK alterations in basal-like IBC. One of 25 patients was identified as having an
EML4-ALK translocation. The generality of gains in ALK copy number in basal-like breast tumors with IBC
characteristics was demonstrated by analysis of 479 breast tumors using the TGCA data-base and our newly
developed 79 IBC-like gene signature. The small molecule dual tyrosine kinase cMET/ALK inhibitor, Crizotinib (PF-
02341066/Xalkori®, Pfizer Inc), induced both cytotoxicity (IC50 = 0.89 μM) and apoptosis, with abrogation of pALK
signaling in IBC tumor cells and in FC-IBC01 tumor xenograft model, a new IBC model derived from pleural effusion
cells isolated from an ALK+ IBC patient. Based on these studies, IBC patients are currently being evaluated for the
presence of ALK genetic abnormalities and when eligible, are being enrolled into clinical trials evaluating ALK
targeted therapeutics.
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Introduction
Inflammatory breast cancer (IBC) is the most metastatic
form of breast cancer (Robertson et al. 2010). IBC ac-
counts for an estimated 24% of cases of advanced stage
(Stage IIIb, IIIc or IV) breast cancers (Buzdar et al.
1995). Inflammatory breast cancer (IBC) has been de-
fined as a clinical-pathologic entity characterized by dif-
fuse erythema and edema (peau d’orange) involving a
third or more of the skin of the breast (American Joint
Committee on Cancer Staging Manual 2010). The
swelling and enlargement of the breast and the appear-
ance of dimpled skin defined as “peau d’ orange” is asso-
ciated with the presence of tightly aggregated tumor
cells, defined as tumor emboli, that have robust expres-
sion of E-cadherin and are encircled by dermal lymph-
atic vessels (Cristofanilli et al. 2007; Vermeulen et al.
2010). The involvement of the dermal lymphatics pro-
vides an avenue for rapid metastasis, associated with the
common clinical and pathological signs of axillary and
other loco-regional lymph node involvement in IBC pa-
tients at the time of first diagnosis (Robertson et al.
2010). Despite the development of multi-modality treat-
ment strategies over the past 30 years that have in-
creased overall survival of patients with non-IBC locally
advanced breast cancers, there has been no significant
change in survival of IBC patients during this same time
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period (Gonzalez-Angulo et al. 2007). The average sur-
vival of IBC patients (2.9 years) is significantly less than
the survival rate of patients diagnosed with non-IBC lo-
cally advanced breast cancer (6.4 years) and the >10-year
survival rate of patients with non-T4 (i.e., non-locally
advanced) breast cancer (Hance et al. 2005).
Only a few genes, such as Rho C GTPase, have been
associated with the invasive phenotype of IBC (Van
Golen et al. 2000; Kleer et al. 2005) and the underlying
genetic changes in IBC remain largely undefined. The
lack of the understanding of the molecular underpin-
nings of IBC points out the critical need to identify ab-
normalities in gene and protein signaling pathways that
are activated in IBC in order to provide new therapeutic
strategies to IBC patients who are routinely excluded
from clinical trials.
The present studies present first time evidence for the
activation of anaplastic lymphoma kinase (ALK) pathway
activation in pre-clinical models of IBC, that was con-
sistent with detection of increased gains in copy num-
bers of ALK, low level ALK gene amplification, ALK
gene expression or more rarely, the presence of EML4-
ALK translocation in IBC breast tumors. Analysis of
breast tumors in the TGCA database revealed a signifi-
cant association between basal-like breast tumors that
have characteristics of IBC breast tumors and gains in
ALK copy number. The dual cMET/ALK inhibitor,
Crizotinib, induced significant cytotoxicity in ALK + IBC
cell lines and in vivo studies revealed that this agent in-
duced significant apoptosis in ALK+ IBC xenografts
which was associated with inhibition of phospho-ALK
signaling activation. Collectively, these results suggest
that ALK serves as a therapeutic target for IBC and indi-
cate that strategies targeting ALK should be considered
for evaluation in clinical trials.
Materials and methods
Cell lines
The SUM149, SUM159 and SUM190 cell lines were pur-
chased from Asterand (Detroit, MI). The MDA-IBC3
cells were obtained from W.A. Woodward and KPL-4
cells were obtained from N. T. Ueno, The University of
Texas MD Anderson Cancer Center. All other cell lines,
AU565, MDA-MB-231, MDA-MB-468, MCF-7, and
SKBR3, were purchased from American Type Culture
Collection (ATCC;Manassas, VA). The new models of
ALK+ IBC, designated as FC-IBC01 and FC-IBC02, were
developed in the laboratories of FM Robertson, The
University of Texas MD Anderson and M Cristofanilli,
Thomas Jefferson University, using tumor cells freshly
isolated from IBC patients with disease progression as
evidenced by pleural effusion. Pleural fluids were re-
moved by thoracentesis using an IRB approved protocol,
with patient consent; tumor cells were isolated and
served as the source to derive new IBC cell lines and
xenograft models (Fernandez et al. 2013). Mary-X is a
stable transplantable IBC xenograft derived from a pa-
tient with primary IBC and developed by Sanford H.
Barsky (Alpaugh et al. 1999). Identity of all cell lines was
validated based on STR analysis performed by the MD
Anderson Cell Analysis core laboratory.
Reverse phase protein microarray analysis
Pathway activation mapping was performed by reverse
phase protein microarray (RPMA) as previously de-
scribed (Paweletz et al. 2001; Wulfkuhle et al. 2008;
Einspahr et al. 2012; Sheehan et al. 2005). Protein signal-
ing analytes were chosen for analysis based on their in-
volvement in key aspects of tumorigenesis: growth,
survival, autophagy, apoptosis, differentiation, adhesion,
motility, and inflammation. All antibodies were validated
for single band specificity as well as for ligand-induction
(for phospho-specific antibodies) by Western Blotting.
Continuous variable RPMA data generated were sub-
jected to both unsupervised and supervised statistical
analysis. Statistical analyses were performed on final
RPMA intensity values obtained using SAS version 9
software or JMP v5.0 (SAS Institute, Cary, NC). Initially,
the distribution of variables was checked. If the distribu-
tion of variables for the analyzed groups (e.g. IBC v non-
IBC) was normal, a two-sample t-test was performed. If
the variances of two groups were equal, two-sample t-test
with a pooled variance procedure was used to compare
the means of intensity between two groups. Otherwise,
two-sample t-test without a pooled variance procedure
was adopted. For non-normally distributed variables, the
Wilcoxon rank sum test was used. All significance levels
were set at p ≤ 0.05.
Analysis of ALK genetic abnormalities
Methods for FISH analysis of ALK genetic abnormalities
were as previously published (Shaw et al. 2011). Results
of the FISH analysis were read by Dr. Guoxian Sun, a
board certified pathologist in the Genzyme Genetics
CLIA approved diagnostic laboratory. Results were inde-
pendently validated by direct PCR and CMA analysis.
Fluorescence microscopy images were taken of each
tumor specimen to quantitate the heterogeneity of ALK
copy number and to assess the location of the FISH
probes.
Chromosomal analysis
Affymetrix CytoScan™ HD arrays were used to evaluate
copy number and loss of heterozygosity (LOH) in sam-
ples of IBC and non-IBC breast cancer cell lines. These
arrays contain more than 2.6 million copy number
markers of which 750,000 are “genotype–able” SNPs and
1.9 million are non–polymorphic probes. DNA was
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isolated using Gentra Puregene Cell kit (Qiagen) based
on manufacturers protocols. Copy number and genotyp-
ing analyses were performed using Affymetrix Chromo-
some Analysis Suite (ChAS) software.
Analysis of ALK gene expression and ALK amplification in
TCGA samples classified as “IBC-like” and non-IBC-like (nIBC)
We recently reported the development of a nearest
shrunken centroid classification model based on the ex-
pression of 79 IBC-specific and molecular subtype-
independent genes that was able to correctly discriminate
between samples from patients with and without IBC (Van
Laere et al. 2013). Using this model, we analyzed a series of
479 samples from patients with non-IBC breast cancer
(nIBC) for which gene expression data were available
through the TCGA project (Cancer Genome Atlas Network
2012). Based on the 79-gene signature that we developed,
tumor samples were classified as either having “IBC-like”
or “nIBC-like” characteristics. Prior to the application of
the model, TCGA expression data were normalized using
regression models to obtain a data distribution compar-
able to the data distribution of the training set on which
the nearest shrunken centroid algorithm has been trained.
To classify the same samples according to the molecular
subtypes, the PAM50 algorithm (Parker et al. 2009) was
applied. Finally, putative ALK copy number alterations
(CNAs), estimated using GISTIC 2.0 were retrieved and
were categorized as follows: -2 = homozygous deletion;
-1 = hemizygous deletion; 0 = neutral/no change; 1 = gain;
2 = high-level amplification. All data (i.e. mRNA expres-
sion data and ALK CNA data) were retrieved from the
World Wide Web (www.cbioportal.org).
Microarray analysis of breast tumor cell lines
Cells were isolated and total RNA was extracted using
RNeasy kits (Qiagen; Gaithersburg, MD), with RNA in-
tegrity determined using an Agilent Bioanalyzer 2100
(Agilent Technologies, Inc; Santa Clara, CA. Whole
transcriptome analysis of cells was performed using
Genechip® U133 p v2 microarray platform (Affymetrix,
Inc; Santa Clara CA) in the RNA core laboratory at the
University of Texas MD Anderson Cancer Center.
Microarrays were scanned using a GeneChip Scanner
7G (Affymetrix, Santa Clara, CA), Microarray date files
were imported using dChip v.1.3 software, Nexus and
IPA algorithms, data was normalized using invariant set
normalization and analyzed to detect significant differ-
ences in gene expression. The output is a log2-
transformed expression index data of each probe set.
Differences between the expression of genes of interest
between IBC cell lines and non-IBC cell lines were ana-
lyzed and are represented as a heatmap.
Analysis of cytotoxicity of Crizotinib in cell lines
Cell proliferation was assayed using the ProMega
CellTiter Cell Proliferation Assay (Promega, Fitchburg,
WI) based on manufacturers protocols. MDA-MB-231,
SUM159, and SUM149 cells were seeded into a 96 well
plate at 1500 cells per well and H2228, MCF-7,
SUM190, MDA-IBC-3, and freshly isolated tumor cells
from the patient designated as FC-IBC01 were seeded at
4000 cells/well, allowed to attach overnight and treated
with Crizotinib (Selleck Chemical, Houston, TX)
dissolved in DMSO at the indicated concentrations. Ex-
periments were terminated at 72 hrs following treat-
ment, processed according to the manufacturer’s
instructions and plates were read at 490 nm using a
BioTek plate reader (Winooski, VT). Data analysis was
performed using Prism GraphPad 5.0 (GraphPad Soft-
ware). Studies were performed at least three times with
similar results.
Xenograft implantation
All experiments involving animals were conducted in ac-
cordance with protocols approved by the University of
Texas MD Anderson Cancer Center Institutional Animal
Care and Use Committee (IACUC). FC-IBC01 cells and
Mary-X cells (5 × 105) were injected either into the
lower left mammary fat pad or subcutaneously into the
hind flanks of female 6–8 week old NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ mice to evaluate primary tumor growth
and for the presence of tumor emboli formation, re-
spectively. Mice bearing tumors of at least 200 mm3
were treated either with 83 mg/kg Crizotinib or DMSO
vehicle control once daily for three days via gavage and
sacrificed at 24 hr following the last dose.
Immunohistochemistry and microscopy
FC-IBC01 and Mary-X tumors and associated skin in
the case of hind flank injection studies were collected
at necropsy and fixed in 10% neutral buffered forma-
lin. Tissues were paraffin-embedded, sectioned, and
stained with H&E. Immunochemical methods used to
stain tissues for phospho-proteins, E-cadherin and
podoplanin are as previously reported (Robertson
et al. 2012). Antibodies used included p-ALK Y-1586
antibody (Abnova, Walnut Creek, CA) p-AKT-Ser-473
(Cell Signaling, Danvers, MA) and p-mTOR-Ser-2448
(Cell Signaling). The DNA dye, TOPRO-3 (Invitrogen/
Life Technologies) was used to identify nuclear DNA.
For negative controls, tissue was processed in the
same way with the omission of primary antibody.
Images were examined and captured using a LSM
510 confocal laser scanning system (Carl Zeiss,
Thornwood, NY) at 25× magnification.
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TUNEL staining and quantitation
Apoptosis was detected using Roche fluorescence la-
beled In situ cell death detection kit, (Roche Applied
Science, Hague, IN), based on manufacturers protocols.
Positive controls tissues for the TUNEL assay were
DMSO treated tissues treated with recombinant DNase I
and negative controls were tissues stained reaction mix-
ture lacking terminal transferase. To quantitate TUNEL
staining, three tumors from separate mice were used for
each of the control and drug treated groups). Images for
TUNEL stained cells and TOPRO-3 labeled nuclei were
captured on five randomly chosen fields for each section.
Image J software (http://rsbweb.nih.gov/ij/) was used to
count the number of stained cells and nuclei. The com-
parison between vehicle control and Crizotinib treated
groups were performed to determine the significance be-
tween groups using Student two-tailed T-test. Quantita-
tion of Crizotinib-induced changes in staining of
p-Akt-Ser473 and p-mTor-Ser2448 were performed
using methods described above.
Western blot analysis of cMET and phospho-cMET
The antibodies directed against total cMET, alpha chain
of phospho-Y1234/1235 cMET and beta chain of
phospho-Y1234/1235 cMET were purchased from Cell
Signaling (Danvers, MA). Protein was normalized to
GAPDH, used as a loading control. Cells were isolated
to obtain cell pellets, which were dried and then lysed in
1% M-PER lysis buffer (Thermo Fisher, Rockford, IL).
Protein concentrations of lysates were determined using
a total protein assay (Bio-Rad Laboratories, Hercules,
CA). Equal amounts of protein (100 μg) were loaded
and then separated using 10% polyacrylamide gels (Bio-
Rad). Proteins were transferred to nitrocellulose mem-
branes (GE Healthcare, Piscataway, NJ), blocked for
non-specific binding using a buffer containing 1X PBS,
0.1% Tween-20, and 5% milk and then probed with
1:1000 dilution of cMET, phospho-cMET antibodies
followed by incubation with horseradish peroxidase-
conjugated secondary antibodies (GE Healthcare). Pro-
tein bands were visualized using Chemiglow enhanced
chemiluminescence system (Alpha Imager, San Leandro,
CA) and densitometric analysis was used to quantitate
changes in proteins. Experiments were repeated three
times and representative Western blots are shown.
Results
Functional protein pathway of breast cancer cell lines
Reverse Phase Protein Microarray (RPMA), which is a
powerful pathway activation mapping technology that
we previously developed and described (Paweletz et al.
2001; Wulfkuhle et al. 2008; Einspahr et al. 2012;
Sheehan et al. 2005), was utilized to map 150 key signal-
ing proteins in human IBC cell lines (Mary-X, MDA-
IBC-3, SUM 190, and SUM 149) and non-IBC human
breast cancer cell lines (MCF7, MDA-MB-468, SUM159,
and MDA-MB-231). RPMA analysis revealed that IBC
cell lines exhibited activation of multiple members of
the ALK receptor tyrosine kinase (RTK) signaling net-
work (Figure 1). This activation included phosphoryl-
ation of ALK itself at the tyrosine (Y) 1586
phosphorylation site, p ≤ 0.05), and activation of the
RTK docking proteins, GAB1 ((Y627), p ≤ 0.02) and
FRS2 alpha (Y436, p ≤ 0.02). In addition, IBC cell lines
exhibited activation of RTK-driven JAK-STAT signaling
(JAK1 (Y1022/1023, p ≤ 0.04), STAT3 (Y705, p ≤ 0.05),
as well as the RTK-driven AKT-mTOR signaling path-
ways, including PDK1 (Serine (S) 241), p ≤ 0.03); AKT
(S473, p ≤ 0.004 and Threonine (T) 308 p ≤ 0.005);
mTOR (S2448, p ≤ 0.02), and AMPK Beta (S108, p ≤
0.05). In contrast, the non-IBC cell lines including MCF-
7, MDA-MB-231, SUM159 and MDA-MB-468 had no
ALK phosphorylation above array background.
ALK in IBC patient tumors
A set of 25 randomly selected IBC patient tumors were
analyzed using the FDA approved fluorescence in situ
hybridization (FISH) detection method based on the
Vysis ALK Break Apart Probe for detection of EML-
4-ALK translocation and gene amplification (Shaw et al.
2011). These studies were performed independently and
reviewed by a board certified pathologist at a CLIA-
approved Genzyme Genetics Laboratory, Dr. Guoxian
Sun. As shown in Table 1, 20/25 IBC patient tumor sam-
ples had some type of ALK genetic aberrations including
ALK copy numbers, ALK gene amplification and in the
case of 1 IBC patient, EML4-ALK translocation. As an
example of the interpretation of FISH analysis for one
IBC sample reflective of the heterogeneity of ALK copy
number alterations or ALK amplification detected in
IBC patients, the report was “negative for rear-
rangements involving the ALK gene, with three to four
copies of ALK observed in 59.0% of cells, five to six cop-
ies of ALK observed in 11.0% of cells and seven to eight
copies of ALK were observed in 6.0% of cells, suggesting
the presence of a neoplasm with gains of chromosome 2
or 2p”. Figure 2A is a two-color immunofluorescence
image of the FISH analysis for this specific IBC sample.
When an ALK rearrangement is present in a tumor,
whether it is an inversion or translocation, one of the
two fusion signals separates as one red and one green
signal (Figure 2B, arrows). As shown in Figure 2B, sepa-
rated signals were present in 1 IBC tumor that had
EML-4-ALK genetic abnormality in 76% of nuclei
scored, which is outside the normal limits. The patterns
observed suggest the presence of a concomitant deletion
of the 5′ centromeric green probe signal, which is a
common finding in NSCLC.
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Analysis of ALK amplification in TCGA-samples classified
as “IBC-like” and “nIBC-like”
Using the 79-gene signature model that we recently de-
veloped (Van Laere et al. 2013), approximately 25% of
TCGA breast tumor samples were classified as “IBC-
like”. Samples classified as “IBC-like” were significantly
more often of the basal-like subtype (65% vs. 10% for
samples classified as “nIBC-like”; P < 0.001). Data on
ALK copy number alterations (CNAs) were available for
455/479 samples of the TGCA database. Hemizygous
deletions of ALK (GISTIC class −1) were reported in 32
samples (7%) and a copy number gain (GISTIC class +1)
was reported in 43 samples (9%). In 380 samples (84%),
no CNAs were detected for ALK. Sixty percent of the
samples with an ALK copy number gain were classified
as “IBC-like” whereas 93% of the samples with a ALK
hemizygous deletion were classified as “nIBC-like” (Chi-
square test; P < 0.001). The posterior probabilities of
samples to be classified as “IBC-like” associated with the
extent of ALK CNAs are provided in boxplot-format in
Figure 2C. All observed differences were statistically sig-
nificant (all P < 0.010). Evaluation of the molecular sub-
types in relationship with ALK CNAs revealed that 72%
of the ALK copy number gains were present in samples
classified as basal-like. In contrast, 80% of the hemizy-
gous ALK deletions were observed in samples classified
as luminal A or luminal B subtypes. Of note, 98% of the
“normal-like” samples classified as ALK copy number
neutral. Given these association, we sought to determine
Table 1 ALK genetic abnormalities in IBC patient tumors
Subtype of IBC patients No. patients with
ALK abnormalities
Percentage of
cells with increase
ALK copy number
ER/PR/Her2 negative 13[1 with EML4-ALK] 16-75%
HR+/Her2 negative 4 9-65%
Her2+ 3 33-51%
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Figure 1 Activation of ALK signaling network in pre-clinical models of IBC. Reverse Phase Protein Microarray analysis of human IBC cell lines
and non-IBC human breast tumor cell lines that were cultured under low adherence conditions supporting self-renewal revealed activation of
multiple members of the receptor tyrosine kinase (RTK) ALK signaling network, including JAK1/STAT3, AKT, mTor, PDK-1 and AMP kinase β. The P
values for the level of phosphorylation of these signaling molecules in IBC cell lines compared with non-IBC cell lines was set at p≤ 0.05 and the
individual P values are described in the Results section.
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the influence of the molecular subtypes on the associ-
ation between ALK CNAs and the “IBC-like”/”nIBC-
like”-classification. Multivariate regression analysis re-
vealed that the “IBC-like”/”nIBC-like” classification was
associated with ALK CNAs, independent of the molecu-
lar subtypes (OR = 1.106; 95%C.I. = 1.001-1.222; P =
0.048). These data suggest that, at least in non-IBC
breast tumors, the presence of ALK copy number alter-
ations were more likely to occur in those tumors that
had characteristics gene expression profiles similar to
those from patients with IBC.
Development of ALK + IBC pre-clinical models
Since there are few pre-clinical IBC models available to
study the effects of the small molecule cMET/ALK in-
hibitor Crizotinib, we developed an ALK+ pre-clinical
model of IBC using tumor cells freshly isolated from
IBC patient with disease progression evidenced by
pleural effusion. Tumor cells were isolated from pleural
effusion of a 48 year old woman with stage IIIC triple
negative IBC at time of initial diagnosis who had re-
ceived neoadjuvant chemotherapy including Cytoxan,
Adriamycin + Taxane, carboplatin and gemcitabine, with
preoperative radiotherapy. She had extensive residual
disease in the breast and local lymph nodes, suggesting
resistant disease. She developed progressive disease a few
weeks following surgery, with symptomatic pleural effu-
sion. Bilateral pleural effusions were visible in the right
quadrant. Pleural fluid was removed by thoracentesis
using an IRB approved protocol, with patient consent, and
these tumor cells, which we designated as FC-IBC01, were
isolated. The freshly isolated FC-IBC01 tumor cells served
as the source of cells to analyze the effects of Crizotinib
and to derive a new IBC cell line and xenograft model
used for to assess ALK gene expression, and in vivo re-
sponse to Crizotinib.
ALK in IBC cell lines and xenograft models
Of the 7 IBC cell lines examined, the newly developed
cell lines and pre-clinical models of IBC designated as
FC-IBC01 and FC-IBC02, in addition to the Mary-X
cells, which all classify within the basal like subtype and
form tumor emboli when injected in vivo, expressed the
highest levels of ALK gene expression (Figure 3A).
Additional file 1: Table S1 shows results of Chromo-
somal Microarray Analysis (CMA) of all IBC cell lines,
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Figure 2 FISH analysis of ALK genetic abnormalities in IBC patient tumors and Levels of ALK Gene Expression in Breast Tumors. A.
Immunofluorescence image of FISH analysis of IBC tumor showing heterogeneity of ALK copy number, varying from 3–8 copies of ALK. B.
Immunofluorescence image of FISH analysis of IBC tumor showing one of the two fusion signals separated as one red and one green signal in
76% of nuclei scored, consistent with the presence of EML4-ALK translocation (arrows). C. The posterior probabilities of samples to be classified as
“IBC-like” in function associated with ALK copy number alterations (CNAs) are shown in boxplot-format. All observed differences were statistically
significant (P ≤ 0.010). There was a positive and significant association between breast tumor samples classified as basal-like with IBC
characteristics and ALK copy number alterations.
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Figure 3 (See legend on next page.)
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revealing that there are a number of ALK genetic abnor-
malities in pre-clinical models of IBC, including increased
copy number, gene amplification (ALK > 3) and in the case
of FC-IBC01 uniparental disomy. This analysis also dem-
onstrated that focal adhesion kinase (FAK) and the stem
cell marker CD44 may also be likely therapeutic targets in
IBC based on their levels of amplification in the pre-
clinical models of IBC that recapitulate the formation of
tumor emboli.
FC-IBC01 tumor cells were injected subcutaneously into
the right hind flanks of NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ mice, and poorly differentiated tumors with high nu-
clear grade and prominent mitotic activity developed within
45 days, with visible invasion through the hypodermis into
the dermal-epidermal junction (Figure 3A). Numerous
tumor emboli were visible within the dermis adjacent to
the primary FC-IBC01 xenograft (Figure 3A, inset) which
were found to have robust expression of E-cadherin (green
fluorescence) (Figure 3C), which is characteristic of the skin
involvement of this variant of breast cancer that is com-
monly observed in IBC patients. The FC-IBC01 tumor em-
boli that expressed E-cadherin were enwrapped by
lymphatic vessels, which are identified by specific staining
for podoplanin (red fluorescence) (Figure 3C). The FC-
IBC01 tumor emboli, which were encircled by lymphatic
endothelium (red fluorescence), also expressed ALK protein
(green fluorescence) (Figure 3D). Nuclear DNA is stained
with the DNA dye TOPRO-3 (blue fluorescence).
IBC tumor cells are sensitive to the small molecule ALK
inhibitor, Crizotinib
The dose response of freshly isolated FC-IBC01 cells to
the small molecule ALK inhibitor, Crizotinib, is shown
in Figure 3E. Crizotinib was cytotoxic against FC-IBC01
cells, with an IC50 of 0.89 μM (Figure 3E; Table 2).
SUM149 cells, which we have found to express phospho-
cMET protein (Additional file 2: Figure S1), were also re-
sponsive to the cytotoxic effects of the dual cMET/ALK
inhibitor, Crizotinib. The range of IC50 doses for the IBC
cell lines that express either ALK or cMET mRNA is con-
sistent with the IC50 concentration of Crizotinib in the
H2888 NSCLC cell line, which has an EML4-ALK trans-
location, and for the IMR-32 neuroblastoma cell line,
IMR-32 (Table 2) which harbors full length wild type
oncogenic ALK. Studies were performed to evaluate the
effects of treatment of mice bearing FC-IBC01 xenografts
with Crizotinib. Treatment of tumor bearing mice with
daily doses of 83 mg/kg Crizotinib administered via gavage
induced significant apoptosis of FC-IBC01 tumor cells,
detected by TUNEL staining as the marker for pro-
grammed cell death (Figure 4A-G). The TUNEL staining
appears as green fluorescence and the nuclear DNA is
stained with the DNA dye TOPRO-3. Figure 4A and B
shows the lack of TUNEL staining in FC-IBC01 xenograft
tissue isolated from mice treated with the DMSO vehicle
control. Figure 4C and D shows the representative in-
crease in TUNEL staining in FC-IBC-01 xenograft tissue
isolated from Crizotinib-treated mice. The positive control
for TUNEL staining is shown in Figures 4E and F. Quanti-
tation of the differences in TUNEL staining between ve-
hicle control and Crizotinib-treated tissues demonstrates
that this agent induced significant levels (P ≤ 0.0001) of
apoptosis (Figure 4G). In addition to the significant apop-
totic response, quantitative image analysis also revealed
that Crizotinib significantly inhibited phospho-ALK-Y-
1604 staining in both the FC-IBC01 and Mary-X models
of IBC (Figure 4H and I; P ≤ 0.0001). Similarly, quantita-
tive analysis of the effects of Crizotinib in xenograft tissues
from mice bearing either FC-IBC01 or Mary-X tumors
(See figure on previous page.)
Figure 3 ALK Gene Expression of Pre-Clinical Models of IBC. A. Analysis of gene expression levels of ER/PR/Her2, EGFR and ALK in each of
the 7 available pre-clinical models of IBC including SUM149, Mary-X, FC-IBC01, FC-IBC02, SUM190, MDA-IBC-3 and KPL-4 cells and non-IBC human
breast tumor cell lines MDA-MB-231, SUM159 and MCF-7. The highest levels of ALK gene expression was detected in the triple negative IBC cell
lines FC-IBC01, FC-IBC02 and Mary-X, which each recapitulate the formation of IBC tumor emboli in vivo. B. Light micrograph of histology of
FC-IBC01 xenograft showing poorly differentiated tumor with high nuclear grade and prominent mitotic activity, with visible invasion through the
hypodermis into the dermal-epidermal junction. Inset: Distinct tumor emboli are visible within the dermal layer of the skin in the H&E section of
FC-IBC01 xenograft tissue (inset). C. Confocal microscopy combined with triple color immunofluorescence staining demonstrates that mice
bearing FC-IBC01 tumors form tumor emboli within the dermis that express E-cadherin (green fluorescence) and are enwrapped by lymphatic
vessels, identified by specific staining for podoplanin (red fluorescence). The DNA dye Topro-3 (blue fluorescence) identifies nuclei. D. FC-IBC01
tumor emboli contain ALK protein (green fluorescence) and are encircled by podoplanin stained lymphatic endothelium (red fluorescence). E.
Dose response analysis of tumors cells freshly isolated from the patient designated as FC-IBC01 demonstrating response to Crizotinib and
resistance to Paclitaxel.
Table 2 IC50 concentrations of Crizotinib
Cell line Crizotinib IC50
FC-IBC01 0.89 μM
Mary-X 0.87 μM
SUM149 0.77 μM
MDA-IBC-3 1.98 μM
SUM190 5.20 μM
KPL-4 6.45 μM
H2228 NSCLC EML4-ALK 0.834 μM
IMR-32 wt ALK 0.74 μM
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demonstrated that this cMET/ALK inhibitor also signifi-
cantly diminished phospho-AKT-serine 473 and phospho-
mTOR ser-2448 signaling activation (data not shown).
Discussion
The ALK receptor tyrosine kinase was initially identified
as a member of the insulin receptor subfamily that ac-
quires transforming capability when it is truncated and
fused to NPM (nucleophosmin) in a chromosomal re-
arrangement that is common in anaplastic large cell
lymphomas (ALCL) and in non-Hodgkin’s lymphoma
with a T cell phenotype (Morris et al. 1994; Wellmann
et al. 1995). Recent focus on ALK as a therapeutic target
occurred due to the discovery of a fusion of ALK with
echinoderm microtubule associated protein 4 (EML4-
ALK) in a population of NSCLC patients who were
highly responsive to the small molecule cMet/ALK in-
hibitor, Crizotinib (Xalkori; Pfizer, Inc, Groton, CT)
(Pillai and Ramalingam 2012; Kwak et al. 2010; Kim
et al. 2012; Tiseo et al. 2011). The clinical efficacy of
Crizotinib in this patient population during early phase
clinical trials paved the way for accelerated FDA ap-
proval of this targeted therapeutic (8/2011), in tandem
with development and FDA approval of a diagnostic test
that detects both EML4-ALK translocation and ALK
copy number, and is used to select patients for enroll-
ment into clinical trials with Crizotinib (Shaw et al.
2011). Recent reports from the results of the PROFILE
study document the superiority of Crizotinib treatment
in NSCLC patients with ALK genetic abnormalities
compared with standard second line chemotherapy
(Shaw et al. 2013; Pilotto et al. 2013). This clinical trial
demonstrates the potential utility of early use of targeted
therapeutics. Multiple other tumor types from a wide
variety of organ sites have now been found to have dif-
ferent ALK abnormalities, other than NPM-ALK and
EML4-ALK fusions, including increased ALK copy num-
ber, ALK amplification, ALK gene expression, missense
point mutations, fusions between ALK and multiple
genes and/or ALK signaling pathway activation (Kelleher
and McDermott 2010). It is now clear that genetic
abnormalities of ALK and ALK signal pathway activation
are present in numerous tumor types, with other ALK
abnormalities still to be discovered. The diversity of
tumor types with a wide variety of ALK genetic abnor-
malities as well as ALK gene expression and activation
of the ALK signaling pathway has prompted the sugges-
tion that a new classification of “Alkomas” be used to
denote tumors that have ALK as an oncogenic driver, re-
gardless of their cell of origin (Mano 2012).
In contrast to studies identifying genetic abnormalities
of ALK in other tumor types, results of investigations
evaluating breast tumors for ALK genetic abnormalities
have been inconsistent. While one study reported that
2.4% of breast tumors had translocation of EML4-ALK
(Fukuyoshi et al. 2008), another study failed to detect
the EML4-ALK fusion gene in breast tumors (Lin et al.
2009). Most recently, Lehmann et al (Lehmann et al.
2011) identified ALK as a signaling pathway important
in triple negative breast cancers (TNBCs) and TNBC cell
lines that had characteristics of mesenchymal cells and
mesenchymal stem cells. Collectively, these observations
suggest that EML4-ALK abnormalities are likely rela-
tively rare in breast cancers in general, with ALK gene
expression and activation of the ALK signaling pathway
more common in TNBC. This observation has import-
ant implications, given that IBC patients typically have
tumors that are either of the TNBC subtype or alterna-
tively are Her-2+ (Van Laere et al. 2013). The observa-
tion of ALK gene expression in TNBC in general is
consistent with the present results demonstrating the
prevalence of increased ALK copy number, low level
gene amplification and/or ALK pathway activation in
IBC pre-clinical models of triple negative IBC; This ob-
servation is also consistent with the detection of ALK
abnormalities in IBC tumors and with the identification
of ALK copy gains in basal-like breast cancers that have
an “IBC-like” gene signature.
Prior to the present studies, few genetic abnormalities
or dysregulated signaling pathways had been identified
in IBC. Using a functional protein pathway activation
mapping approach coupled with genomic analysis
(See figure on previous page.)
Figure 4 Effects of Crizotinib in Pre-clinical Models of ALK + IBC. A-B. Treatment of mice bearing FC-IBC01 xenografts with DMSO vehicle
control had no detectable apoptosis as determined by detection of TUNEL staining as a marker of programmed cell death. Figure 4 A shows the
lack of green fluorescence associated with TUNEL staining and Figure 4 B shows a lack of green fluorescence which detects TUNEL staining, with
detection of blue fluorescence which is associated with nuclear DNA based on Topro-3 staining. C and D. Treatment of mice bearing FC-IBC01
xenografts with 83 mg/kg Crizotinib resulted in significant apoptosis of FC-IBC01 tumor cells, as assessed by detection of TUNEL as a marker for
programmed cell death, as denoted by the green fluorescence (Figure 4 C) and double label of green fluorescence which detects TUNEL staining
and blue fluorescence detects nuclear DNA based on Topro-3 staining (Figure 4 D). E and F. Positive control for TUNEL staining using DNAse I
treatment of xenograft tissues. G. Comparative quantitative analysis of Crizotinib-induced apoptosis in FC-IBC01 tumor xenografts demonstrates a
significant increase in detection of TUNEL positive cells (P ≤ 0.0001). H and I. Comparative analysis of inhibitory effects of Crizotinib on phospho-
ALK-Y-1604 signaling activation in FC-IBC01 and Mary-X pre-clinical models of IBC. Treatment of mice bearing FC-IBC01 (H) or Mary-X (I) with
83 mg/kg Crizotinib significantly inhibited phospho-ALK- Y-1604 (P≤ 0.0001).
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approach, the present studies are the first to identify
ALK signaling as a potential driver in pre-clinical models
of IBC that recapitulate the formation of tumor emboli
when grown as xenografts which we demonstrate have
either ALK signaling activation, low level gene amplifica-
tion, and/or ALK gene expression. These results suggest
that IBC is characterized as having multiple changes in
ALK that can occur at the gene level or at the protein
pathway activation level. Based on these results, IBC pa-
tients are currently being screened for ALK genetic abnor-
malities and if eligible, have the opportunity to participate
in clinical trials with ALK inhibitors [http://clinicaltrials.
gov/show/NCT01283516]. Collectively, these studies rep-
resent an example of precision medicine focused on trans-
lating pre-clinical observations to benefit patients with
this unique and lethal form of breast cancer.
Additional files
Additional file 1: Table S1. Chromosomal Microarray Analysis of Pre-
Clinical Models of IBC.
Additional file 2: Figure S1. Comparative western blot analysis of total
cMET protein and the 45 kD alpha chain and 145 kD beta chain forms of
phospho-tyrosine (Y 1234/1235) cMET in 13 human breast tumor cell
lines. The mature 45 KD form of cMET was detected primarily in SUM149
IBC cells as well as in AU565, MDA-MB-231, SUM159 and MDA-MB-468
breast tumor cells. The 145 kD beta chain form of phospho-Y 1234/1235
cMET was present in SUM149 cells, in SUM190, MDA-IBC3 and KPL-4 IBC
cells and in AU565, MDA-MB 231, SUM159, MDA-MB-468 and in SKBR3
human breast tumor cells. In contrast, the 45 kD alpha chain form of
phospho- Y 1234/1235 cMET was generally produced at low levels and
detected in SUM149 IBC cells as well as in SUM159 breast tumor cells.
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